Prostate cancer
CA071-1000
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Trial overview
Clinical Area
Medical Oncology
Disease
Prostate
Disease site
Genitourinary (GU)
Study Phase
III
Trial Identifiers
Registration number: NCT06764485
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries